Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY...

Area of Science:

• Cardiology
• Pharmacology

Background:

• Atrial fibrillation (AF) carries a modest risk of myocardial infarction (MI) and other ischemic events.
• Understanding the comparative safety of anticoagulants in AF is crucial for patient management.

Purpose of the Study:

• To compare the rates of MI and other myocardial ischemic events between dabigatran and warfarin in patients with atrial fibrillation.
• To evaluate the net clinical benefit and treatment effects of dabigatran versus warfarin.

Main Methods:

• Analysis of data from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) study.
• Comparison of annual event rates for MI, unstable angina, cardiac arrest, cardiac death, and a composite of these events.
• Assessment of prespecified "net clinical benefit" outcomes including all strokes, systemic embolism, MI, pulmonary embolism, major bleeding, and all-cause death.

Main Results:

• Annual MI rates were 0.82% with dabigatran 110 mg, 0.81% with dabigatran 150 mg, and 0.64% with warfarin (nonsignificant increase with dabigatran).
• Composite rates of MI, unstable angina, cardiac arrest, and cardiac death were similar between dabigatran (3.16%-3.33%) and warfarin (3.41%).
• Net clinical benefit events occurred at 7.34% (dabigatran 110 mg), 7.11% (dabigatran 150 mg), and 7.91% (warfarin) per year, with a significant benefit for dabigatran 150 mg.

Conclusions:

• Dabigatran demonstrated a nonsignificant increase in MI risk but did not increase other myocardial ischemic events compared to warfarin.
• Treatment effects were consistent across patient subgroups with or without a history of MI or coronary artery disease.
• Dabigatran, particularly at 150 mg BID, showed a favorable net clinical benefit profile in patients with atrial fibrillation.